Evidence map›Paper›PMID 37354199›Full record

ArticleHypertension (Dallas, Tex. : 1979)2023

Editors' Commentary on the 2023 ESH Management of Arterial Hypertension Guidelines.

Paul K Whelton, John M Flack, Garry Jennings, Alta Schutte, Jiguang Wang, Rhian M Touyz

Open access · greenAbstract readComment
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. High-intensity interval training attenuates urothelial nerve growth factor and angiotensin axis in hypertensive urinary bladder.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. What Constitutes Adequate Control of High Blood Pressure? Current Considerations.Mayo Clinic proceedings. Innovations, quality & outcomes · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Paul K WheltonDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (P.K.W.).ORCID 0000-0002-2225-383X
John M FlackHypertension Section, Division of General Medicine, Department of Medicine, Southern Illinois University, Springfield (J.M.F.).ORCID 0000-0003-2584-5598
Garry JenningsSydney Health Partners, University of Sydney and National Heart Foundation, New South Wales, Australia (G.J.).ORCID 0000-0002-7865-5483
Alta SchutteSchool of Population Health, University of New South Wales, The George Institute for Global Health, Sydney, Australia (A.S.).ORCID 0000-0001-9217-4937
Jiguang WangShanghai Institute of Hypertension, Shanghai Jiao Tong University School of Medicine, China (J.W.).ORCID 0000-0001-8511-1524
Rhian M TouyzDepartment of Medicine, Faculty of Medicine and Health Sciences, McGill University, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada (R.M.T.).ORCID 0000-0003-0670-0887
McGill University Health Centre · CANational Heart Foundation of Australia · AUShanghai Institute of Hypertension · CNSouthern Illinois University School of Medicine · USTulane University · USUNSW Sydney · AU

Funding

Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Katherine Teresa Mills · 2016 to 2026
$25.3M
NIGMS NIH HHS P20 GM109036
6 · The paper itself

Abstract

Clinical practice guidelines are ideally suited to the provision of advice on the prevention, diagnosis, evaluation, and management of high blood pressure (BP). The recently published European Society of Hypertension (ESH) 2023 ESH Guidelines for the management of arterial hypertension is the latest in a long series of high BP clinical practice guidelines. It closely resembles the 2018 European Society of Cardiology/ESH guidelines, with incremental rather than major changes. Although the ESH guidelines are primarily written for European clinicians and public health workers, there is a high degree of concordance between its recommendations and those in the other major BP guidelines. Despite the large number of national and international BP guidelines around the world, general population surveys demonstrate that BP guidelines are not being well implemented in any part of the world. The level of BP, which is the basis for diagnosis and management, continues to be poorly measured in routine clinical practice and control of hypertension remains suboptimal, even to a conservative BP target such as a systolic/diastolic BP <140/90 mm Hg. BP guidelines need to focus much more on implementation of recommendations for accurate diagnosis and strategies for improved control in those being treated for hypertension. An evolving body of implementation science can assist in meeting this goal. Given the enormous health, social, and financial burden of high BP, better diagnosis and management should be an imperative for clinicians, government, and others responsible for the provision of health care services. Hopefully, the 2023 ESH will help enable this.

Indexed as

CardiologyHypertensionAntihypertensive AgentsBlood PressureBlood Pressure DeterminationHumansAntihypertensive Agentsantihypertensive agentscardiologyfinancial stressgoalsgovernmenthypertensionpractice guideline

Identifiers

PMID37354199
PMCPMC10527435
OpenAlexW4381890475

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.